Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients.

Muro Y, Sugiura K, Akiyama M.

Autoimmunity. 2013 Jun;46(4):279-84. doi: 10.3109/08916934.2012.755958. Epub 2013 Feb 8.

PMID:
23215730
2.

Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort.

Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A.

J Immunol Methods. 2012 Oct 31;384(1-2):128-34. doi: 10.1016/j.jim.2012.07.019. Epub 2012 Aug 2.

PMID:
22884621
3.

Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.

Muro Y, Ishikawa A, Sugiura K, Akiyama M.

Rheumatology (Oxford). 2012 Aug;51(8):1508-13. doi: 10.1093/rheumatology/kes073. Epub 2012 Apr 25.

PMID:
22539482
4.

Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis.

Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, McHugh NJ; UK Adult Onset Myositis Immunogenetic Collaboration.

Ann Rheum Dis. 2009 Oct;68(10):1621-5. doi: 10.1136/ard.2008.097162. Epub 2008 Oct 17.

PMID:
18930994
5.

Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.

Merlo G, Clapasson A, Cozzani E, Sanna L, Pesce G, Bagnasco M, Burlando M, Parodi A.

Arch Dermatol Res. 2017 Mar;309(2):87-95. doi: 10.1007/s00403-016-1704-1. Epub 2016 Dec 7.

PMID:
27928683
6.

Recent advances in dermatomyositis-specific autoantibodies.

Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N.

Curr Opin Rheumatol. 2016 Nov;28(6):636-44. doi: 10.1097/BOR.0000000000000329. Review.

PMID:
27533321
7.

Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.

Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T.

Rheumatology (Oxford). 2010 Sep;49(9):1726-33. doi: 10.1093/rheumatology/keq153. Epub 2010 May 25.

PMID:
20501546
8.

Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.

Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szöllősi L, Dankó K.

Autoimmun Rev. 2014 Dec;13(12):1211-9. doi: 10.1016/j.autrev.2014.08.011. Epub 2014 Aug 23. Review.

PMID:
25182203
9.

Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis.

Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Tincani A, Selmi C, Chan JY, Chan EK, Satoh M, Franceschini F.

Clin Exp Rheumatol. 2014 Nov-Dec;32(6):891-7. Epub 2014 Aug 15.

PMID:
25151986
10.

Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2.

Ishikawa A, Muro Y, Sugiura K, Akiyama M.

Rheumatology (Oxford). 2012 Jul;51(7):1181-7. doi: 10.1093/rheumatology/kes033. Epub 2012 Mar 16.

PMID:
22427409
11.

A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.

Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK.

Clin Rev Allergy Immunol. 2017 Feb;52(1):1-19. doi: 10.1007/s12016-015-8510-y. Review.

PMID:
26424665
12.

Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis.

Yamasaki Y, Yamada H, Nozaki T, Akaogi J, Nichols C, Lyons R, Loy AC, Chan EK, Reeves WH, Satoh M.

Arthritis Rheum. 2006 Jun;54(6):2004-9.

13.

Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis: comparison with a UK Caucasian cohort.

Fujimoto M, Matsushita T, Hamaguchi Y, Kaji K, Asano Y, Ogawa F, Yamaoka T, Fujikawa K, Tsukada T, Sato K, Echigo T, Hasegawa M, Takehara K.

Ann Rheum Dis. 2013 Jan;72(1):151-3. doi: 10.1136/annrheumdis-2012-201736. Epub 2012 Jul 26. No abstract available.

PMID:
22843487
14.

Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis.

Chen Z, Hu W, Wang Y, Guo Z, Sun L, Kuwana M.

Clin Rheumatol. 2015 Sep;34(9):1627-31. doi: 10.1007/s10067-015-2935-9. Epub 2015 Apr 24.

PMID:
25903820
15.

Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.

Ceribelli A, Isailovic N, De Santis M, Generali E, Fredi M, Cavazzana I, Franceschini F, Cantarini L, Satoh M, Selmi C.

Clin Rheumatol. 2017 Feb;36(2):469-475. doi: 10.1007/s10067-016-3453-0. Epub 2016 Oct 20.

PMID:
27761751
16.

Clinical significance of specific autoantibodies in juvenile dermatomyositis.

Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED.

J Rheumatol. 1996 Oct;23(10):1794-7.

PMID:
8895161
17.

Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients.

Kang EH, Kuwana M, Okazaki Y, Lee EY, Lee YJ, Lee EB, Song YW.

Mod Rheumatol. 2014 Nov;24(6):945-8. doi: 10.3109/14397595.2014.896494. Epub 2014 Mar 26.

PMID:
24670134
18.

[Autoantibodies specifically detected in patients with polymyositis/dermatomyositis].

Sato S.

Nihon Rinsho Meneki Gakkai Kaishi. 2006 Apr;29(2):85-93. Review. Japanese.

20.

Supplemental Content

Support Center